Efficacy and Safety of Perioperative Angiotensin II Versus Phenylephrine as a First‐Line Continuous Infusion Vasopressor in Kidney Transplant Recipients
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15432 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Lyra P Beltran und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, University of Illinois Chicago College of Pharmacy, Denver, Colorado, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Vasoconstrictor Agents, Phenylephrine, Angiotensin II. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Angiotensin II (ATII) maintains blood pressure via RAAS with a beneficial adverse effect profile versus catecholamines and phenylephrine. Head‐to‐head data comparing ATII to phenylephrine are lacking regarding renal allograft function, hemodynamic efficacy, and safety within the perioperative period of kidney transplantation.
Methods
This single‐center, retrospective study included adult kidney transplant recipients who received continuous infusions of ATII or phenylephrine within a 24‐h perioperative period as a first‐line vasopressor according to an institutional algorithm. The primary endpoint was allograft function. Secondary endpoints were hemodynamic efficacy and adverse effects.
Results
Among 105 patients, there was no significant difference in IGF ( p = 0.545), SGF ( p = 0.557), or DGF ( p = 0.878) between patient cohorts. In the 34 patients with cold ischemia time (CIT) > 14‐h, IGF was higher ( p = 0.013) and DGF ( p = 0.045) was lower in the ATII cohort versus phenylephrine. In all patients, ATII was associated with a decreased need for additional vasopressor agents ( p < 0.001). Adverse effect profiles were similar between cohorts ( p > 0.05).
Conclusion
Among kidney transplant recipients, ATII may be a suitable first‐line alternative compared with phenylephrine in the perioperative period for hypotension management with a reduced need for additional vasopressor support. Allograft benefits were observed in patients with prolonged CIT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, University of Illinois Chicago College of Pharmacy, Denver, Colorado, USA.
- Department of Surgery, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA.
- Department of Surgery, Division of Transplantation, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA.
- Division of Clinical Anesthesiology, Department of Medicine, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA.
- University of Illinois Chicago College of Pharmacy, Denver, Colorado, USA.
ORCID-Profile: Lyra P Beltran, Jamie Benken, Enrico Benedetti, Rachel M Belcher, Scott T Benken
Zitieren
APA
Beltran, L. P., Benken, J., Jou, J., Benedetti, E., Nishioka, H., Alamreia, E., Belcher, R. M., & Benken, S. T. (2024). Efficacy and Safety of Perioperative Angiotensin II Versus Phenylephrine as a First‐Line Continuous Infusion Vasopressor in Kidney Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.15432
Vancouver
Beltran LP, Benken J, Jou J, Benedetti E, Nishioka H, Alamreia E, et al. Efficacy and Safety of Perioperative Angiotensin II Versus Phenylephrine as a First‐Line Continuous Infusion Vasopressor in Kidney Transplant Recipients. Clinical Transplantation. 2024. doi:10.1111/ctr.15432
BibTeX
@article{Beltran2024,
author = {Beltran, Lyra P and Benken, Jamie and Jou, Jonathan and Benedetti, Enrico and Nishioka, Hokuto and Alamreia, Enas and Belcher, Rachel M and Benken, Scott T},
title = {Efficacy and Safety of Perioperative Angiotensin II Versus Phenylephrine as a First‐Line Continuous Infusion Vasopressor in Kidney Transplant Recipients},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15432}
}
EUVIMED